Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Meyer Cancer Center, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Meyer Cancer Center, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Dermatology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Curr Opin Genet Dev. 2024 Oct;88:102238. doi: 10.1016/j.gde.2024.102238. Epub 2024 Jul 31.
Epitranscriptomic modification of tRNA has recently gained traction in the field of cancer biology. The presence of such modifications on tRNA appears to allow for translational control of processes central to progression and malignant transformation. Methyltransferase Like 1 protein (METTL1), along with other epitranscriptomic writers (e.g. NSUN3, NAT10, ELP3, etc.), has recently been investigated in multiple cancer types. Here, we review the impact of such tRNA modifications in tumorigenesis and the progression of cancer toward drug resistance and metastasis. Regulation of central cellular processes relied upon by malignant cancer cells through modulation of the tRNA epitranscriptome represents an area with great potential to bring novel first-in-class therapies to the clinic.
tRNA 的转录后修饰最近在癌症生物学领域引起了关注。tRNA 上存在这些修饰似乎允许对与进展和恶性转化相关的过程进行翻译控制。甲基转移酶样蛋白 1(METTL1)以及其他转录后修饰酶(如 NSUN3、NAT10、ELP3 等)最近在多种癌症类型中得到了研究。在这里,我们综述了这种 tRNA 修饰在肿瘤发生以及癌症向耐药性和转移进展过程中的作用。通过调节 tRNA 转录组来调节恶性癌细胞依赖的细胞内核心过程,代表了为临床带来新型首创疗法的巨大潜力。